62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y http://www.zacks.com/stock/news/304716/dr-reddys-rdy-q4-earnings-fall-revenues-decline-y-y?cid=CS-ZC-FT-304716 May 23, 2018 - Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
Even in This Rich Market, Celgene Is Offering Investors Value https://www.fool.com/investing/2018/05/10/even-in-this-rich-market-celgene-is-offering-inves.aspx?source=iedfolrf0000001 May 10, 2018 - This beaten-down biotech stock should still be a solid winner for patient investors.
BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod http://www.zacks.com/stock/news/297425/biomarins-maa-for-phenylketonuria-candidate-gains-eu-nod?cid=CS-ZC-FT-297425 Mar 29, 2018 - BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.
3 Things You'll Want to Know From Celgene's 1st Public Event After the Ozanimod Debacle https://www.fool.com/investing/2018/03/14/3-things-youll-want-to-know-from-celgenes-1st-publ.aspx?source=iedfolrf0000001 Mar 14, 2018 - The biotech's CFO talks about the future for ozanimod, challenges to Revlimid, and more at the Barclays healthcare conference.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals http://www.zacks.com/stock/news/295256/zacks-industry-outlook-highlights-astrazeneca-bayer-dr-reddys-laboratories-teva-pharmaceuticals-and-adamas-pharmaceuticals?cid=CS-ZC-FT-295256 Mar 12, 2018 - Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Pharma Stocks Weighed Down by Competition, Generic Pressure http://www.zacks.com/commentary/152552/pharma-stocks-weighed-down-by-competition-generic-pressure?cid=CS-ZC--152552 Mar 09, 2018 - Pharma Stocks Weighed Down by Competition, Generic Pressure
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised) http://www.zacks.com/stock/news/292663/jj-jnj-gets-fda-nod-for-new-prostate-cancer-treatment-revised?cid=CS-ZC-FT-292663 Feb 15, 2018 - J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Dr. Reddy's Laboratories' (RDY) Management on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4140207-dr-reddys-laboratories-rdy-management-q3-2018-results-earnings-call-transcript?source=feed_tag_india Jan 25, 2018 - Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) Q3 2018 Earnings Conference Call January 25, 2018 8:00 AM ET Executives Saunak Savla – Head-Investor Relations Saumen Chakraborty – President, Chief Financial
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y http://www.zacks.com/stock/news/290129/dr-reddys-rdy-q3-earnings-fall-revenues-improve-y-y?cid=CS-ZC-FT-290129 Jan 25, 2018 - Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
3 Top Generic Drug Stocks to Consider Buying Now https://www.fool.com/investing/2017/12/20/3-top-generic-drug-stocks-to-consider-buying-now.aspx?source=iedfolrf0000001 Dec 20, 2017 - Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.

Pages: 1234567

<<<Page 3>